CombiGene AB (publ) (COMBI.ST)
SEK 2.7
(-0.74%)
SEK 2.7
(-0.74%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -101.44 Million SEK | 23.02% |
| 2022 | -131.77 Million SEK | 3.63% |
| 2021 | -136.74 Million SEK | -179.67% |
| 2020 | -48.89 Million SEK | -692.99% |
| 2019 | -6.16 Million SEK | 80.61% |
| 2018 | -31.8 Million SEK | -546.68% |
| 2017 | -4.91 Million SEK | -60.99% |
| 2016 | -3.05 Million SEK | 67.42% |
| 2015 | -9.37 Million SEK | -80.56% |
| 2014 | -5.19 Million SEK | -40813.42% |
| 2013 | -12.69 Thousand SEK | -20370.97% |
| 2012 | -62.00 SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -83.55 Million SEK | 7.49% |
| 2024 Q1 | -90.31 Million SEK | 10.96% |
| 2023 Q3 | -107.18 Million SEK | 7.15% |
| 2023 Q2 | -115.44 Million SEK | 4.2% |
| 2023 Q4 | -101.44 Million SEK | 5.36% |
| 2023 FY | -101.44 Million SEK | 23.02% |
| 2023 Q1 | -120.5 Million SEK | 8.55% |
| 2022 Q2 | -125.95 Million SEK | -3.52% |
| 2022 Q3 | -144.94 Million SEK | -15.07% |
| 2022 Q4 | -131.77 Million SEK | 9.08% |
| 2022 FY | -131.77 Million SEK | 3.63% |
| 2022 Q1 | -121.66 Million SEK | 11.03% |
| 2021 FY | -136.74 Million SEK | -179.67% |
| 2021 Q4 | -136.74 Million SEK | -106.91% |
| 2021 Q3 | -66.08 Million SEK | 19.77% |
| 2021 Q2 | -82.37 Million SEK | -141.64% |
| 2021 Q1 | -34.09 Million SEK | 30.28% |
| 2020 FY | -48.89 Million SEK | -692.99% |
| 2020 Q3 | -35.24 Million SEK | -95.52% |
| 2020 Q2 | -18.02 Million SEK | -88.85% |
| 2020 Q4 | -48.89 Million SEK | -38.73% |
| 2020 Q1 | -9.54 Million SEK | -54.8% |
| 2019 Q4 | -6.16 Million SEK | -62.9% |
| 2019 FY | -6.16 Million SEK | 80.61% |
| 2019 Q2 | -21.83 Million SEK | 22.63% |
| 2019 Q3 | -3.78 Million SEK | 82.67% |
| 2019 Q1 | -28.22 Million SEK | 11.25% |
| 2018 Q1 | -4.6 Million SEK | 6.39% |
| 2018 Q2 | -3.56 Million SEK | 22.65% |
| 2018 Q4 | -31.8 Million SEK | -91.95% |
| 2018 FY | -31.8 Million SEK | -546.68% |
| 2018 Q3 | -16.56 Million SEK | -365.29% |
| 2017 Q1 | -11.91 Million SEK | -290.03% |
| 2017 Q3 | -7.67 Million SEK | 6.45% |
| 2017 Q4 | -4.91 Million SEK | 35.94% |
| 2017 FY | -4.91 Million SEK | -60.99% |
| 2017 Q2 | -8.2 Million SEK | 31.13% |
| 2016 FY | -3.05 Million SEK | 67.42% |
| 2016 Q3 | -5.98 Million SEK | 22.63% |
| 2016 Q1 | -9.66 Million SEK | -2.16% |
| 2016 Q4 | -3.05 Million SEK | 48.97% |
| 2016 Q2 | -7.73 Million SEK | 19.94% |
| 2015 Q4 | -9.46 Million SEK | 11.02% |
| 2015 Q2 | -12.72 Million SEK | -204.23% |
| 2015 Q1 | -4.18 Million SEK | 19.46% |
| 2015 FY | -9.37 Million SEK | -80.56% |
| 2015 Q3 | -10.63 Million SEK | 16.43% |
| 2014 Q4 | -5.19 Million SEK | 0.0% |
| 2014 FY | -5.19 Million SEK | -40813.42% |
| 2014 Q1 | 12.69 Thousand SEK | 0.0% |
| 2013 FY | -12.69 Thousand SEK | -20370.97% |
| 2012 FY | -62.00 SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -102.795% |
| Ziccum AB (publ) | -2.13 Million SEK | -4646.841% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -432.214% |
| BioArctic AB (publ) | -606.58 Million SEK | 83.277% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -103.148% |
| Mendus AB (publ) | -96.29 Million SEK | -5.344% |
| Genovis AB (publ.) | -43.94 Million SEK | -130.855% |
| Intervacc AB (publ) | -88.16 Million SEK | -15.064% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 594.588% |
| Active Biotech AB (publ) | -33.2 Million SEK | -205.542% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 290.594% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -157.58% |
| Aptahem AB (publ) | 2.9 Million SEK | 3587.538% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 69.594% |
| Kancera AB (publ) | -45.69 Million SEK | -122.008% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 69.173% |
| Fluicell AB (publ) | -2.76 Million SEK | -3571.372% |
| Saniona AB (publ) | 40.44 Million SEK | 350.797% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -217.725% |
| Biovica International AB (publ) | -58.73 Million SEK | -72.702% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -124.34% |
| AcouSort AB (publ) | -23.98 Million SEK | -322.913% |
| Xintela AB (publ) | -7.8 Million SEK | -1199.014% |
| Abliva AB (publ) | -57.24 Million SEK | -77.219% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 47.899% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -23.403% |
| OncoZenge AB (publ) | -12.62 Million SEK | -703.358% |
| Amniotics AB (publ) | -5.63 Million SEK | -1701.136% |
| 2cureX AB (publ) | -13.4 Million SEK | -656.845% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -4594.123% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1978.519% |
| Camurus AB (publ) | -1.16 Billion SEK | 91.295% |
| Corline Biomedical AB | -17.01 Million SEK | -496.285% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -21.133% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 26.572% |
| I-Tech AB | -83.26 Million SEK | -21.832% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 175.304% |
| Cyxone AB (publ) | -16.67 Million SEK | -508.518% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -81.512% |
| Biosergen AB | -1.88 Million SEK | -5287.148% |
| Cantargia AB (publ) | -139.74 Million SEK | 27.412% |
| NextCell Pharma AB | -46.79 Million SEK | -116.796% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 21.665% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -245.234% |
| Nanologica AB (publ) | -9.38 Million SEK | -980.528% |
| SynAct Pharma AB | -61.75 Million SEK | -64.254% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -373.687% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -666.79% |
| LIDDS AB (publ) | -13.51 Million SEK | -650.74% |
| Lipum AB (publ) | -8.46 Million SEK | -1098.346% |
| BioInvent International AB (publ) | -236.3 Million SEK | 57.072% |
| Alzinova AB (publ) | -21.22 Million SEK | -377.904% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -51.584% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1857.953% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -21.135% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -10890.249% |
| Simris Alg AB (publ) | 85.07 Million SEK | 219.236% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -23.578% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 161.08% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -387.856% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -3313.19% |